4.4 Article

Growth Suppression Effects of Recombinant Adenovirus Expressing Human Lactoferrin on Cervical Cancer In Vitro and In Vivo

Journal

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Volume 26, Issue 4, Pages 477-483

Publisher

MARY ANN LIEBERT INC
DOI: 10.1089/cbr.2010.0937

Keywords

adenovirus; apoptosis; cervical cancer; gene therapy; human lactoferrin

Funding

  1. Research on transgenic animal with disease resistance of Major Technology Project of Ministry of Agriculture program of China [2009ZX08007-008B]
  2. Science and Technology Investing Company, Qinhungdao, China

Ask authors/readers for more resources

Human lactoferrin (hLF) is a multifunctional glycoprotein that can inhibit cancer growth. The molecular mechanism of hLF-induced tumor growth inhibition is incompletely understood. Moreover, the adenovirus vector-mediated hLF (Ad-hLF) gene therapy on cervical cancer has not been yet characterized. In this study, the replication-deficient Ad-hLF was used to explore tumor growth suppression effects on cervical cancer in vitro and in vivo. The results showed that the recombinant adenovirus encoding hLF delivery resulted in a more differential tumor growth inhibition, and this growth arrest was caused by cell cycle inhibition at G2/M phase. In addition, Fas, a death-inducing receptor, and Bax, a member of pro-apoptotic Bcl-2 family, were increased in the sample of cervical cancer tissue treated by Ad-hLF. Further, it was also observed that caspase-3 was activated and the expression of antiapoptotic Bcl-2 was decreased. These results indicated that the growth inhibitory effects of Ad-hLF on cervical cancer were caused by elevated expression of Fas and decreased the ratio of anti-to pro-apoptotic molecule Bcl-2/Bax.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available